Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.
about
PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure.Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapseThe diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.Oxysterol receptors and their therapeutic applications in cancer conditions.Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI.Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients.68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer.Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.[(68)Ga-PSMA as a new tracer for evaluation of prostate cancer: comparison between PET-CT and PET-MRI in biochemical recurrence].See the unseen: Mesorectal lymph node metastases in prostate cancer.
P2860
Q30365461-36CD7AA7-F956-4E4D-8230-12B42CEFF940Q33408024-14D5D25C-ED06-4498-8866-2DDA7AEECF33Q33668676-F71F251F-5457-4C12-A483-F721B595C293Q35043569-DF0B166F-2F6A-4936-8581-8E4A1C296916Q37350456-58AD4B19-2CB6-47B3-A27C-BF7A74BFC826Q38123210-A038F0A7-D46F-4436-9BE3-7A49E5F78E89Q38683427-A21624F1-54EE-418C-8BE7-2345A92D4E6CQ47109640-4DF38B1E-095D-4A2A-984C-A98E3CC182A4Q47147617-80820B82-4540-452B-86D8-120C0A373308Q48905216-83DC9589-EA9F-48D7-8FB4-523DA8226483Q52991043-C52B45FE-AF3C-4026-98AD-2DB5E4B95254Q53031006-F791CDE4-FCAF-4C50-BD14-810CA2276FD2Q53174206-C680E8A8-F608-42E7-8F4F-46CCDF36C4EC
P2860
Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Review of salvage therapy for ...... ne antigen radioimmunotherapy.
@ast
Review of salvage therapy for ...... ne antigen radioimmunotherapy.
@en
type
label
Review of salvage therapy for ...... ne antigen radioimmunotherapy.
@ast
Review of salvage therapy for ...... ne antigen radioimmunotherapy.
@en
prefLabel
Review of salvage therapy for ...... ne antigen radioimmunotherapy.
@ast
Review of salvage therapy for ...... ne antigen radioimmunotherapy.
@en
P2093
P2860
P356
P1433
P1476
Review of salvage therapy for ...... ne antigen radioimmunotherapy.
@en
P2093
Michael Smith
Naveed H Akhtar
Satyajit Kosuri
Scott T Tagawa
P2860
P304
P356
10.1155/2012/921674
P577
2012-05-28T00:00:00Z